---
schema_version: "secwatch.filing_event.v1"
accession: "0001185185-24-000233"
form_type: "8-K"
ticker: "IGC"
cik: "0001326205"
company_name: "IGC Pharma, Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:04:37.185173+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IGC Pharma appoints Terry Lierman as independent director to advance Alzheimer's pipeline

## Summary
- Terry Lierman appointed as independent Class B director, effective March 12, 2024.
- Lierman brings healthcare leadership: co-chair IHV, founder of Children's Research Institute, PanCAN, NOFAS.
- Granted options to buy 150,000 shares at $0.30/share; 50,000 vest immediately, balance over 2025-2026.
- His expertise will support Phase 2 trial of IGC-AD1 for agitation in Alzheimer's and preclinical TGR-63.
- CEO Ram Mukunda cites Lierman's strategic guidance as pivotal for pipeline advancement.

## SEC filing metadata
- accession: 0001185185-24-000233
- form_type: 8-K
- ticker: IGC
- cik: 0001326205
- company_name: IGC Pharma, Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326205/000118518524000233/0001185185-24-000233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326205/000118518524000233/igcpharma20240311_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001185185-24-000233
- JSON: https://secwatch.observer/filing/0001185185-24-000233.json
- Plain text: https://secwatch.observer/filing/0001185185-24-000233.txt

## Key facts
- Executive change
  Terry Lierman was appointed as independent Class B director at IGC Pharma, Inc..
  - Action: appointed
  - Role: independent Class B director
  source text: On March 12, 2024, the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company” or “IGC”) appointed Mr. Terry Lierman (“Mr. Lierman”) to serve on the Board as a Class B director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326205/000118518524000233/0001185185-24-000233-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.